{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:55:53Z","timestamp":1790646953600,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007321","name":"Centro Pfizer-Universidad de Granada-Junta de Andaluc\u00eda de Gen\u00f3mica e Investigaci\u00f3n Oncol\u00f3gic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04543-x","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:16:02Z","timestamp":1790597762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)"],"prefix":"10.1007","author":[{"given":"Ignacio Pel\u00e1ez","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica Blanco","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo Garc\u00eda","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Iglesias","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ic\u00edar Garc\u00eda","family":"Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Feliciangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray Galv\u00e1n","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-8474","authenticated-orcid":false,"given":"Alfonso G\u00f3mez","family":"de Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P\u00e9rez","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Rodr\u00edguez","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo S\u00e1nchez-Escribano","family":"Morcuende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Su\u00e1rez","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Emilio L\u00e1zaro","family":"Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-3488","authenticated-orcid":false,"given":"Enrique Gallardo","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7541-9832","authenticated-orcid":false,"given":"Josep Gum\u00e0 i","family":"Padr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos Villa","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Garc\u00eda","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia Mart\u00ednez","family":"Kareaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen Beato","family":"Zambrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8075-0666","authenticated-orcid":false,"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Ruiz","family":"Cabrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munarriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina Giron\u00e9s","family":"Sarri\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Fern\u00e1ndez","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Alonso","family":"Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-5254","authenticated-orcid":false,"given":"Emilio","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"8","key":"4543_CR1","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530\u201340. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2530.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4543_CR2","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted agents: results from a large multicenter study. J Clin Oncol. 2009;27(34):5794\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.21.4809.","journal-title":"J Clin Oncol"},{"key":"4543_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"4543_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7\u2013H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089\u201396.","journal-title":"Cancer Res"},{"key":"4543_CR5","doi-asserted-by":"publisher","first-page":"709s","DOI":"10.1158\/1078-0432.CCR-06-1868","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007;13:709s\u201315s.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"4543_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006369","volume":"96","author":"Q Wang","year":"2017","unstructured":"Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore). 2017;96(18):e6369. https:\/\/doi.org\/10.1097\/MD.0000000000006369.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4543_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11523-015-0392-7","volume":"11","author":"R Iacovelli","year":"2016","unstructured":"Iacovelli R, Nol\u00e8 F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma: a systematic review and meta-analysis. Target Oncol. 2016;11(2):143\u20138.","journal-title":"Target Oncol"},{"key":"4543_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02841-7","author":"K M\u00f6ller","year":"2021","unstructured":"M\u00f6ller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, et al. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. Int Urol Nephrol. 2021. https:\/\/doi.org\/10.1007\/s11255-021-02841-7.","journal-title":"Int Urol Nephrol"},{"issue":"Suppl 7","key":"4543_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.7_suppl.418","volume":"33","author":"BI Rini","year":"2015","unstructured":"Rini BI, Yearly J, Dhakal H, Przybycin C. Association of PD-1 and PD-L1 protein expression in matched primary and metastatic renal cell carcinoma tumors. J Clin Oncol. 2015;33(Suppl 7):Abstract 418.","journal-title":"J Clin Oncol"},{"key":"4543_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/CAS.14019","author":"S Mikami","year":"2019","unstructured":"Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, et al. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer Sci. 2019. https:\/\/doi.org\/10.1111\/CAS.14019.","journal-title":"Cancer Sci"},{"issue":"9","key":"4543_CR11","first-page":"14595","volume":"8","author":"X Feng","year":"2015","unstructured":"Feng X, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med. 2015;8(9):14595\u2013603.","journal-title":"Int J Clin Exp Med"},{"key":"4543_CR12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1634\/theoncologist.2015-0151","volume":"20","author":"SJ Shin","year":"2015","unstructured":"Shin SJ, Jeon YK, Cho YM, Lee JL, Chung DH, Park JY, et al. The association between PD-L1 expression and clinical outcomes to VEGF-targeted therapy in metastatic clear cell renal cell carcinoma. Oncologist. 2015;20:1253\u201360.","journal-title":"Oncologist"},{"issue":"15 Suppl","key":"4543_CR13","doi-asserted-by":"publisher","first-page":"3021a","DOI":"10.1200\/jco.2013.31.15_suppl.3021","volume":"31","author":"DJ Figueroa","year":"2013","unstructured":"Figueroa DJ, Liu Y, Gagnon RC, Carpenter C, Dar M, Bartlett-Pandite AN. Correlation of PD-L1 tumor expression and outcomes in RCC patients treated with pazopanib. J Clin Oncol. 2013;31(15 Suppl):3021a.","journal-title":"J Clin Oncol"},{"key":"4543_CR14","unstructured":"Agilent Technologies. PD-L1 IHC 22C3 pharmDx Rx Only SK006 50 tests for use with Autostainer Link 48. Carpinteria: Agilent Technologies; 2020. p. 37."},{"issue":"282","key":"4543_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381. https:\/\/doi.org\/10.1080\/01621459.1958.10501452.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"4543_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2344317","volume":"135","author":"R Peto","year":"1972","unstructured":"Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A Gen. 1972;135(2):185\u2013207. https:\/\/doi.org\/10.2307\/2344317.","journal-title":"J R Stat Soc Ser A Gen"},{"issue":"2","key":"4543_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34(2):187\u2013220.","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"18","key":"4543_CR18","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell","year":"1982","unstructured":"Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543\u201352. https:\/\/doi.org\/10.1001\/jama.1982.03320430047030.","journal-title":"JAMA"},{"key":"4543_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1993","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Figueroa DJ, Fay AP, Liu Y, Signoretti S, Gagnon RC, et al. Correlation of PD-L1 tumor expression and treatment outcomes in RCC patients receiving sunitinib or pazopanib: results from COMPARZ. Clin Cancer Res. 2015. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1993.","journal-title":"Clin Cancer Res"},{"key":"4543_CR20","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1158\/1078-0432.CCR-19-1135","volume":"25","author":"A Flaifel","year":"2019","unstructured":"Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, et al. Data from PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in mRCC: METEOR and CABOSUN analysis. Clin Cancer Res. 2019;25:6080\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1135.","journal-title":"Clin Cancer Res"},{"key":"4543_CR21","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7\u2013H1 in RCC patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101:17174\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4543_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0071","author":"J Hand","year":"2022","unstructured":"Hand J, Ponce F, Hund S, Peltz L, Adams M, Moquin D, et al. High scoring precision demonstrated in multiple tumor indications stained with PD-L1 IHC 22C3 pharmDx used with CPS. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0071.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4543_CR23","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/j.clgc.2021.07.010","volume":"19","author":"M Sorokina","year":"2021","unstructured":"Sorokina M, Stupichev D, Lyu Y, Ramachandran A, Miheecheva N, Brown JH, et al. Diagnostic utility of RNA-Seq for evaluation of PD-L1 expression in clear cell RCC. Clin Genitourin Cancer. 2021;19(6):e374\u201381. https:\/\/doi.org\/10.1016\/j.clgc.2021.07.010.","journal-title":"Clin Genitourin Cancer"},{"key":"4543_CR24","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/0008-5472.CAN-08-0869","volume":"68","author":"RH Thompson","year":"2008","unstructured":"Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, et al. Serum-soluble B7x is elevated in RCC patients and associated with advanced stage. Cancer Res. 2008;68:6054\u20138.","journal-title":"Cancer Res"},{"issue":"7","key":"4543_CR25","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","volume":"17","author":"X Frigola","year":"2011","unstructured":"Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, et al. Identification of a soluble form of B7\u2013H1 that retains immunosuppressive activity and is associated with aggressive RCC. Clin Cancer Res. 2011;17(7):1915\u201323.","journal-title":"Clin Cancer Res"},{"key":"4543_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040667","author":"G Larrinaga","year":"2021","unstructured":"Larrinaga G, Danel J, Solano-Iturri P, Errarte M, Unda M, Loizaga-Iriarte A, et al. Soluble PD-L1 is an independent prognostic factor in clear cell RCC. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040667.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4543_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jcp-2023-208848","volume":"76","author":"JH Park","year":"2023","unstructured":"Park JH, Luchini C, Nottegar A, Tizaoui K, Koyanagi A, Ogino S, et al. Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 cancers: a systematic review and meta-analysis. J Clin Pathol. 2023;76(7):450\u20136. https:\/\/doi.org\/10.1136\/jcp-2023-208848.","journal-title":"J Clin Pathol"},{"issue":"7\u20138","key":"4543_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1159\/000506296","volume":"104","author":"M Shen","year":"2020","unstructured":"Shen M, Chen G, Xie Q, Li X, Xu H, Wang H, et al. Association between PD-L1 expression and prognosis and clinicopathologic features of RCC: a systematic review and meta-analysis. Urol Int. 2020;104(7\u20138):533\u201341. https:\/\/doi.org\/10.1159\/000506296.","journal-title":"Urol Int"},{"issue":"2","key":"4543_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.21037\/tau.2020.01.21","volume":"9","author":"Y Lu","year":"2020","unstructured":"Lu Y, Song Y, Xu Y, Ou N, Liang Z, Hu R, et al. Prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in RCC patients: systematic review and meta-analysis. Transl Androl Urol. 2020;9(2):367\u201381. https:\/\/doi.org\/10.21037\/tau.2020.01.21.","journal-title":"Transl Androl Urol."},{"issue":"1","key":"4543_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.21037\/tau-20-969","volume":"10","author":"Y Xie","year":"2021","unstructured":"Xie Y, Chen Z, Zhong Q, Chen Y, Shangguan W, Xie W. Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic drugs in first-line mRCC: a systematic review and meta-analysis. Transl Androl Urol. 2021;10(1):300\u20139. https:\/\/doi.org\/10.21037\/tau-20-969.","journal-title":"Transl Androl Urol."},{"key":"4543_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102295","volume":"100","author":"C Ciccarese","year":"2021","unstructured":"Ciccarese C, Iacovelli R, Porta C, Procopio G, Bria E, Astore S, et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in mRCC patients with favorable IMDC prognosis. Cancer Treat Rev. 2021;100:102295. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102295.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"4543_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/08923973.2024.2315462","volume":"46","author":"H Yan","year":"2024","unstructured":"Yan H, Xing Z, Liu S, Gao P, Guo G. Factors affecting ICI-combined therapy in metastatic RCC: a meta-analysis. Immunopharmacol Immunotoxicol. 2024;46(3):302\u201318. https:\/\/doi.org\/10.1080\/08923973.2024.2315462.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"7","key":"4543_CR33","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/cancers12071945","volume":"12","author":"A Carretero-Gonz\u00e1lez","year":"2020","unstructured":"Carretero-Gonz\u00e1lez A, Lora D, Mart\u00edn Sobrino I, S\u00e1ez Sanz I, Bourlon MT, et al. The value of PD-L1 expression as predictive biomarker in metastatic RCC: meta-analysis of randomized clinical trials. Cancers (Basel). 2020;12(7):1945. https:\/\/doi.org\/10.3390\/cancers12071945.","journal-title":"Cancers (Basel)"},{"key":"4543_CR34","unstructured":"Albiges L, Suarez Rodriguez C, Procopio G, Bex A, Gruenwald V, Schmidinger M, et al\u00a0First-line randomized study platform to optimize treatment in metastatic RCC: CARE1 pragmatic clinical trial. Horizon Europe. No. 101104801."},{"issue":"9","key":"4543_CR35","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.3390\/ijms24097946","volume":"24","author":"CU Monjaras-Avila","year":"2023","unstructured":"Monjaras-Avila CU, Lorenzo-Leal AC, Luque-Badillo AC, D\u2019Costa N, Chavez-Mu\u00f1oz C, Bach H. The tumor immune microenvironment in clear cell RCC. Int J Mol Sci. 2023;24(9):7946. https:\/\/doi.org\/10.3390\/ijms24097946.","journal-title":"Int J Mol Sci"},{"key":"4543_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/S13000-018-0742-8","author":"H Tatl\u0131","year":"2018","unstructured":"Tatl\u0131 H, Do\u011fan M, Bilgin K, Kilicarslan A, Nahit A, Sendur B, et al. Prognostic significance of PD-L1 expression in clear cell RCC and correlation with tumor microenvironment and HIF expression. Diagn Pathol. 2018. https:\/\/doi.org\/10.1186\/S13000-018-0742-8.","journal-title":"Diagn Pathol"},{"key":"4543_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2015.11.029","author":"Y Messai","year":"2016","unstructured":"Messai Y, Gad S, Zaeem N, Le Teuff G, Couv\u00e9 S, Janji B, et al. Renal cell carcinoma PD-L1, a new direct target of HIF-2\u03b1, is regulated by VHL mutation status. Eur Urol. 2016. https:\/\/doi.org\/10.1016\/J.EURURO.2015.11.029.","journal-title":"Eur Urol"},{"key":"4543_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/S12964-021-00742-X","author":"S Yang","year":"2021","unstructured":"Yang S, Tan J, Miao Y, Zhang Q. The role of PD-L1 in immune dysfunction mediating hypoxia-induced multiple organ injury. Cell Commun Signal. 2021. https:\/\/doi.org\/10.1186\/S12964-021-00742-X.","journal-title":"Cell Commun Signal"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04543-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:03:06Z","timestamp":1790643786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04543-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":38,"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04543-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective multicenter study was conducted in accordance with the Declaration of Helsinki and applicable national regulations. The study protocol was approved by the Ethics Committee of Hospital Universitario Ram\u00f3n y Cajal (CEIm), Madrid, Spain (approval number: 2024-00012-21).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the study and the inclusion of deceased patients, the requirement for written informed consent was waived by the Ethics Committee.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}